Alain Dupuy

Alain Dupuy

Auto-generated profile, based on publicly available information

Alain Dupuy

Department of Dermatology Univ Rennes, CHU Rennes Rennes France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2012 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
SCSarah Beaussant Cohen
Sarah Beaussant Cohen
OFOdile Fenneteau
Odile Fenneteau
EPEmmanuel Plouvier
Emmanuel Plouvier
PRPierre-Simon Rohrlich
Pierre-Simon Rohrlich
GDGerard Daltroff
Gerard Daltroff
JDJean Donadieu
Jean Donadieu
Background: WHIM syndrome (WS), a rare congenital neutropenia due to mutations of the CXCR4 chemokine receptor, is associated with Human Papillomavirus (HPV)-induced Warts, Hypogammaglobulinemia, bacterial Infections and Myelokathexis. The long term follow up of eight patients highlights the clinical heterogeneity of this disease as well as the main therapeutic approaches and remaining challenges in the light of the recent development of new CXCR4 inhibitors.Objective: This study aims to describe the natural history of WS based on a French cohort of 8 patients.Methods: We have reviewed the clinical, biological and immunological features of patients with WS enrolled into the French Severe Chronic Neutropenia Registry.Results: We identified four pedigrees with WS comprised of eight patients and one foetus. Estimated incidence for WS was of 0.23 per million births. Median age at the last visit was 29 years. Three pedigrees encompassing seven patients and the fetus displayed autosomal dominant heterozygous mutations of theCXCR4gene, while one patient presented a wild-typeCXCR4gene. Two subjects exhibited congenital conotruncal heart malformations. In addition to neutropenia and myelokathexis, all patients presented deep monocytopenia and lymphopenia. Seven patients presented repeated bacterial Ears Nose Throat as well as severe bacterial infections that were curable with antibiotics. Four patients with late onset prophylaxis developed chronic obstructive pulmonary disease (COPD). Two patients reported atypical mycobacteria infections which in one case may have been responsible for one patient’s death due to liver failure at the age of 40.6 years. HPV-related disease manifested in five subjects and progressed as invasive vulvar carcinoma with a fatal course in one patient at the age of 39.5 years. In addition, two patients developed T cell lymphoma skin cancer and basal cell carcinoma at the age of 38 and 65 years.Conclusions: Continuous prophylactic anti-infective measures, when started in early childhood, seem to effectively prevent further bacterial infections and the consequent development of COPD. Long-term follow up is needed to evaluate the effect of early anti-HPV targeted prophylaxis on the development of skin and genital warts.

1 March 2006 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CPClaire Pellet
Claire Pellet
DKDelphine Kerob
Delphine Kerob
ADAlain Dupuy
Alain Dupuy
MCMary V. Carmagnat
Mary V. Carmagnat
Samia MourahSamia Mourah
Samia Mourah
Céleste LebbéCéleste Lebbé
Céleste Lebbé

1 October 2014 in Chest
Verified
Journal Article
Closed access
CDCatherine Droitcourt
Catherine Droitcourt
MRMichel Rybojad
Michel Rybojad
RPRaphaël Porcher
Raphaël Porcher
CJCaroline Juillard
Caroline Juillard
ACAnne Cosnes
Anne Cosnes
ADAlain Dupuy
Alain Dupuy

11 October 2017 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
APA. Polat
A. Polat
MDM. Dinulescu
M. Dinulescu
SFS. Fraitag
S. Fraitag
SNS. Nimubona
S. Nimubona
FTF. Toutain
F. Toutain
ADA. Dupuy
A. Dupuy

10 October 2022 in European Journal of Cancer
Verified
Journal Article
Closed access
MVMarie Véron
Marie Véron
SCSylvie Chevret
Sylvie Chevret
JGJean-Jacques Grob
Jean-Jacques Grob
MBMarie Beylot-Barry
Marie Beylot-Barry
PSPhilippe Saiag
Philippe Saiag
LMLaurent Mortier
Laurent Mortier

6 July 2023 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CECécile Ertus
Cécile Ertus
LSLucie-Marie Scailteux
Lucie-Marie Scailteux
ALAlain Lescoat
Alain Lescoat
PBPauline Berthe
Pauline Berthe
VAVincent Auffret
Vincent Auffret
CDCatherine Droitcourt
Catherine Droitcourt
On the basis of safety data on patients with inflammatory rheumatism or inflammatory bowel disease, treatment with Janus kinase (JAK) inhibitors has been linked to the occurrence of major adverse cardiovascular events (MACEs). However, these inflammatory diseases are pro-atherogenic; in contrast, patients with atopic dermatitis (AD) do not usually have a high cardiovascular (CV) comorbidity burden. We systematically searched the PubMed, Embase, Cochrane Library and Google Scholar databases from their inception to September 2nd, 2022. Cohort studies, randomized controlled trials and pooled safety analyses providing CV safety data on patients taking JAK inhibitors for AD were selected. We included patients aged 12 and over. We built a “controlled-period” cohort (9,309 patients: 6,000 exposed to JAK inhibitors and 3,309 exposed to comparators) and an “all JAK inhibitors” cohort (9,118 patients exposed to a JAK inhibitor in any of the included studies). The primary outcome was a composite of acute coronary syndrome (ACS), ischemic stroke, and CV death. The broader secondary MACE outcome encompassed ACS, stroke (whether ischemic or hemorrhagic), transient ischemic attack, and CV death. The frequency of primary and secondary MACEs was assessed in both cohorts. A fixed-effects meta-analysis using Peto’s method was used to calculate the odds ratio (OR) [95% confidence interval (CI)] for MACEs in the “controlled-period” cohort. Risk of bias evaluation was made using the Cochrane Risk of bias tool version 2. Certainty of evidence used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. Eight percent of the initially identified records met the selection criteria, corresponding to 23 records included in the “all JAK inhibitors” cohort”. The patients had been exposed to baricitinib, upadacitinib, abrocitinib, ivarmacitinib, placebo or dupilumab. Four primary events (3 with JAK inhibitors and 1 with placebo) and 5 secondary events (4 with JAK inhibitors and 1 with placebo) occurred among 9,309 patients in the “controlled-period” cohort (MACE frequency = 0.04 % and 0.05%, respectively). Eight primary events and 13 secondary events occurred among 9,118 patients in the “all JAK inhibitors” cohort (MACE frequency = 0.08 and 0.14 %, respectively). Odds ratio for primary MACEs in patients with AD treated with JAK inhibitors compared to placebo or dupilumab was 1.35 (95% CI 0.15-12.21; I2, 12%, very low certainty of evidence). Our review highlighted rare cases of MACE among JAK inhibitors users for AD. Janus kinase inhibitors may have little to no effect on the occurrence of MACEs in patients with AD compared to comparators but the evidence is very uncertain. Real-life, long-term, population-level safety studies are needed.